|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HNRNPH3 |
Gene summary for HNRNPH3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HNRNPH3 | Gene ID | 3189 |
| Gene name | heterogeneous nuclear ribonucleoprotein H3 | |
| Gene Alias | 2H9 | |
| Cytomap | 10q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A024QZK8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3189 | HNRNPH3 | AEH-subject1 | Human | Endometrium | AEH | 1.98e-05 | 9.97e-02 | -0.3059 |
| 3189 | HNRNPH3 | AEH-subject2 | Human | Endometrium | AEH | 7.06e-09 | -2.18e-01 | -0.2525 |
| 3189 | HNRNPH3 | AEH-subject3 | Human | Endometrium | AEH | 3.63e-06 | -2.17e-01 | -0.2576 |
| 3189 | HNRNPH3 | AEH-subject4 | Human | Endometrium | AEH | 2.84e-03 | -8.68e-03 | -0.2657 |
| 3189 | HNRNPH3 | EEC-subject1 | Human | Endometrium | EEC | 5.47e-08 | -9.99e-02 | -0.2682 |
| 3189 | HNRNPH3 | EEC-subject2 | Human | Endometrium | EEC | 2.56e-05 | -1.79e-01 | -0.2607 |
| 3189 | HNRNPH3 | EEC-subject3 | Human | Endometrium | EEC | 7.25e-30 | -2.21e-01 | -0.2525 |
| 3189 | HNRNPH3 | EEC-subject4 | Human | Endometrium | EEC | 4.05e-03 | -1.89e-01 | -0.2571 |
| 3189 | HNRNPH3 | GSM5276934 | Human | Endometrium | EEC | 5.28e-38 | 6.28e-01 | -0.0913 |
| 3189 | HNRNPH3 | GSM5276937 | Human | Endometrium | EEC | 5.72e-36 | 7.00e-01 | -0.0897 |
| 3189 | HNRNPH3 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 8.33e-31 | -1.36e-01 | -0.1869 |
| 3189 | HNRNPH3 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 3.21e-28 | -2.85e-02 | -0.1875 |
| 3189 | HNRNPH3 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 4.97e-36 | 2.94e-02 | -0.1883 |
| 3189 | HNRNPH3 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 2.34e-30 | 1.78e-02 | -0.1934 |
| 3189 | HNRNPH3 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 3.60e-50 | -1.53e-01 | -0.1917 |
| 3189 | HNRNPH3 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.39e-46 | -1.93e-01 | -0.1916 |
| 3189 | HNRNPH3 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 2.29e-10 | 1.35e-01 | -0.1269 |
| 3189 | HNRNPH3 | LZE2T | Human | Esophagus | ESCC | 3.78e-02 | 9.49e-01 | 0.082 |
| 3189 | HNRNPH3 | LZE4T | Human | Esophagus | ESCC | 2.03e-20 | 7.88e-01 | 0.0811 |
| 3189 | HNRNPH3 | LZE7T | Human | Esophagus | ESCC | 5.57e-06 | 8.70e-01 | 0.0667 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000838016 | Endometrium | AEH | RNA splicing | 111/2100 | 434/18723 | 2.42e-17 | 1.12e-14 | 111 |
| GO:004348416 | Endometrium | AEH | regulation of RNA splicing | 55/2100 | 148/18723 | 1.28e-16 | 5.49e-14 | 55 |
| GO:000037515 | Endometrium | AEH | RNA splicing, via transesterification reactions | 88/2100 | 324/18723 | 1.11e-15 | 3.91e-13 | 88 |
| GO:000037715 | Endometrium | AEH | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 87/2100 | 320/18723 | 1.51e-15 | 4.78e-13 | 87 |
| GO:000039815 | Endometrium | AEH | mRNA splicing, via spliceosome | 87/2100 | 320/18723 | 1.51e-15 | 4.78e-13 | 87 |
| GO:000838017 | Endometrium | EEC | RNA splicing | 111/2168 | 434/18723 | 2.45e-16 | 1.13e-13 | 111 |
| GO:004348417 | Endometrium | EEC | regulation of RNA splicing | 55/2168 | 148/18723 | 5.21e-16 | 1.95e-13 | 55 |
| GO:000037516 | Endometrium | EEC | RNA splicing, via transesterification reactions | 88/2168 | 324/18723 | 7.46e-15 | 2.63e-12 | 88 |
| GO:000037716 | Endometrium | EEC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 87/2168 | 320/18723 | 9.97e-15 | 3.15e-12 | 87 |
| GO:000039816 | Endometrium | EEC | mRNA splicing, via spliceosome | 87/2168 | 320/18723 | 9.97e-15 | 3.15e-12 | 87 |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0043484111 | Esophagus | ESCC | regulation of RNA splicing | 116/8552 | 148/18723 | 3.18e-16 | 2.38e-14 | 116 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
| GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:004348412 | Liver | Cirrhotic | regulation of RNA splicing | 85/4634 | 148/18723 | 2.03e-17 | 2.83e-15 | 85 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HNRNPH3 | SNV | Missense_Mutation | rs756561116 | c.400N>A | p.Asp134Asn | p.D134N | P31942 | protein_coding | tolerated(0.12) | probably_damaging(0.956) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| HNRNPH3 | SNV | Missense_Mutation | novel | c.88G>A | p.Glu30Lys | p.E30K | P31942 | protein_coding | deleterious(0.02) | probably_damaging(0.989) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
| HNRNPH3 | SNV | Missense_Mutation | c.422N>C | p.Asp141Ala | p.D141A | P31942 | protein_coding | tolerated(0.59) | benign(0) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HNRNPH3 | SNV | Missense_Mutation | c.34N>A | p.Asp12Asn | p.D12N | P31942 | protein_coding | tolerated(0.11) | possibly_damaging(0.665) | TCGA-AA-3956-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HNRNPH3 | SNV | Missense_Mutation | c.697N>A | p.Ala233Thr | p.A233T | P31942 | protein_coding | tolerated(0.13) | possibly_damaging(0.53) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| HNRNPH3 | SNV | Missense_Mutation | c.674N>C | p.Ile225Thr | p.I225T | P31942 | protein_coding | tolerated(0.06) | possibly_damaging(0.753) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HNRNPH3 | SNV | Missense_Mutation | novel | c.425G>A | p.Gly142Glu | p.G142E | P31942 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| HNRNPH3 | SNV | Missense_Mutation | novel | c.431N>C | p.Asp144Ala | p.D144A | P31942 | protein_coding | tolerated(0.23) | benign(0.026) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| HNRNPH3 | SNV | Missense_Mutation | rs758395261 | c.614N>A | p.Arg205His | p.R205H | P31942 | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| HNRNPH3 | SNV | Missense_Mutation | novel | c.649N>T | p.Pro217Ser | p.P217S | P31942 | protein_coding | deleterious(0.04) | possibly_damaging(0.595) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |